The implants have indications to treat de novo spinal infections. Icotec is the first company to earn the FDA’s clearance for stabilizing the spine in infection cases such as discitis, osteomyelitis, pyogenic infection of the intervertebral disc and other spondylopathies.
BlackArmor implants have reduced artifacts from radiolucent carbon/PEEK material, which improves imaging postoperatively.
Along with the FDA nod, CMS approved BlackArmor implants for its New Technology Add-on Payment, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.